alzheimers disease
Item
1. have had a diagnosis of probable alzheimer's disease
boolean
C0002395 (UMLS CUI [1])
gender; age
Item
2. men or women ages greater than or equal to 55 years and living in the community at the time of enrollment (ie, not living in a rest home or nursing care facility).
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
informed consent
Item
3. signed the subject informed consent form (icf) and is willing and able to participate for the duration of the study.
boolean
C0021430 (UMLS CUI [1])
language comprehension
Item
4. ability to read and understand english, dutch, danish, flemish, french, german, italian, spanish or swedish to ensure compliance with cognitive testing and study visit procedures.
boolean
C0233733 (UMLS CUI [1])
mental retardation; education
Item
5. at least 6 years of education, or sufficient work history to exclude mental retardation.
boolean
C0025362 (UMLS CUI [1])
C0013658 (UMLS CUI [2])
contraception status female; postmenopausal
Item
6. female subjects must be surgically sterile or postmenopausal for > 1 year.
boolean
C0420837 (UMLS CUI [1,1])
C0086287 (UMLS CUI [1,2])
C0232970 (UMLS CUI [2])
vision; hearing
Item
7. adequate vision and hearing to participate in study assessments.
boolean
C0042789 (UMLS CUI [1])
C0018767 (UMLS CUI [2])
caregiver
Item
8. subjects must have a reliable caregiver who can read, understand and speak same language.
boolean
C0085537 (UMLS CUI [1])
dementia
Item
1. current evidence of other causes of dementia.. .
boolean
C0497327 (UMLS CUI [1])
malignancy; basal cell carcinoma; squamous cell carcinoma ; prostate cancer
Item
2. history of, or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. men with prostate cancer may be enrolled at the discretion of the sponsor.
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0007137 (UMLS CUI [3])
C0600139 (UMLS CUI [4])
investigational therapy; immunotherapy
Item
3. use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of ad immunotherapy prior to screening.
boolean
C0949266 (UMLS CUI [1,1])
C0205420 (UMLS CUI [1,2])
C0021083 (UMLS CUI [2])
major surgery
Item
4. major surgery and related complications not resolved within 12 weeks prior to day 1.
boolean
C0679637 (UMLS CUI [1])
Study Subject Participation Status
Item
5. previous participation in an mpc-7869 clinical study.
boolean
C2348568 (UMLS CUI [1])